SE9801148D0 - New receptors - Google Patents

New receptors

Info

Publication number
SE9801148D0
SE9801148D0 SE9801148A SE9801148A SE9801148D0 SE 9801148 D0 SE9801148 D0 SE 9801148D0 SE 9801148 A SE9801148 A SE 9801148A SE 9801148 A SE9801148 A SE 9801148A SE 9801148 D0 SE9801148 D0 SE 9801148D0
Authority
SE
Sweden
Prior art keywords
vdrr
polypeptides
methods
polypeptide
novel
Prior art date
Application number
SE9801148A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Berkenstam
Mats Dahlberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703745A external-priority patent/SE9703745D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9801148A priority Critical patent/SE9801148D0/xx
Publication of SE9801148D0 publication Critical patent/SE9801148D0/xx
Priority to US09/143,828 priority patent/US7118885B2/en
Priority to AU90131/98A priority patent/AU732079B2/en
Priority to KR1020007004011A priority patent/KR20010031120A/ko
Priority to PCT/SE1998/001548 priority patent/WO1999019354A1/en
Priority to CNB988112264A priority patent/CN1134452C/zh
Priority to JP2000515925A priority patent/JP2001519441A/ja
Priority to EP98941985A priority patent/EP1023323A1/en
Priority to NZ504025A priority patent/NZ504025A/xx
Priority to CA002306453A priority patent/CA2306453A1/en
Priority to US11/369,263 priority patent/US20060228778A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9801148A 1997-10-14 1998-03-31 New receptors SE9801148D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9801148A SE9801148D0 (sv) 1997-10-14 1998-03-31 New receptors
CA002306453A CA2306453A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
NZ504025A NZ504025A (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
KR1020007004011A KR20010031120A (ko) 1997-10-14 1998-08-31 신규한 비타민 디 수용체 연관된 폴리펩티드, 이를인코딩하는 핵산 서열 및 이의 용도
AU90131/98A AU732079B2 (en) 1997-10-14 1998-08-31 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
US09/143,828 US7118885B2 (en) 1997-10-14 1998-08-31 Nucleic acid encoding vitamin D receptor related polypeptide
PCT/SE1998/001548 WO1999019354A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CNB988112264A CN1134452C (zh) 1997-10-14 1998-08-31 新的维生素d受体相关多肽、编码其的核苷酸序列及其用途
JP2000515925A JP2001519441A (ja) 1997-10-14 1998-08-31 新規ビタミンｄ受容体関連ポリペプチド、かかるポリペプチドをコードする核酸配列及びその使用
EP98941985A EP1023323A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
US11/369,263 US20060228778A1 (en) 1997-10-14 2006-03-06 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703745A SE9703745D0 (sv) 1997-10-14 1997-10-14 New receptors
SE9801148A SE9801148D0 (sv) 1997-10-14 1998-03-31 New receptors

Publications (1)

Publication Number Publication Date
SE9801148D0 true SE9801148D0 (sv) 1998-03-31

Family

ID=26663102

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801148A SE9801148D0 (sv) 1997-10-14 1998-03-31 New receptors

Country Status (9)

Country Link
EP (1) EP1023323A1 (sl)
JP (1) JP2001519441A (sl)
KR (1) KR20010031120A (sl)
CN (1) CN1134452C (sl)
AU (1) AU732079B2 (sl)
CA (1) CA2306453A1 (sl)
NZ (1) NZ504025A (sl)
SE (1) SE9801148D0 (sl)
WO (1) WO1999019354A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031129A1 (en) * 1997-12-12 1999-06-24 Merck & Co., Inc. DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6911537B2 (en) * 1998-01-09 2005-06-28 The Salk Institute For Biological Studies Xenobiotic compound modulated expression systems and uses therefor
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
AU2003200641B2 (en) * 1998-01-09 2008-04-03 The Salk Institute For Biological Studies Novel Steroid-activated Nuclear Receptors and Uses therefor
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
EP1066320A4 (en) * 1998-03-27 2005-03-16 Glaxo Group Ltd ORPHAN NUCLEAR RECEPTOR
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
AU2006200258B2 (en) * 1999-12-09 2009-04-09 The Salk Institute For Biological Studies Novel steroid-activated nuclear receptors and uses therefor
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
US20040053866A1 (en) * 2002-08-21 2004-03-18 The Regents Of The University Of California Tumor suppressor genes and their uses
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009223A1 (en) * 1988-03-30 1989-10-05 Arch Development Corporation Dna binding proteins including androgen receptor
ATE215601T1 (de) * 1991-09-17 2002-04-15 Salk Inst For Biological Studi Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
AU711041B2 (en) * 1995-01-17 1999-10-07 Salk Institute For Biological Studies, The Methods, polypeptides, nucleotide sequence of XOR-6, a vitamin D-like receptor from xenopus
WO1996036230A1 (en) * 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
CA2306453A1 (en) 1999-04-22
CN1134452C (zh) 2004-01-14
JP2001519441A (ja) 2001-10-23
WO1999019354A9 (en) 1999-12-02
CN1279689A (zh) 2001-01-10
AU732079B2 (en) 2001-04-12
NZ504025A (en) 2003-04-29
AU9013198A (en) 1999-05-03
EP1023323A1 (en) 2000-08-02
KR20010031120A (ko) 2001-04-16
WO1999019354A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
Skowyra et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex
Watterson et al. Structural similarities between the Ca2+-dependent regulatory proteins of 3': 5'-cyclic nucleotide phosphodiesterase and actomyosin ATPase.
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
Wang et al. Cloning and expressional characterization of a novel galanin receptor: identification of different pharmacophores within galanin for the three galanin receptor subtypes
Teichmann et al. Human TATA-binding protein-related factor-2 (hTRF2) stably associates with hTFIIA in HeLa cells
Todorov et al. Characterization of a cancer cachectic factor
Luo et al. Transcriptional inhibition by Stat5: differential activities at growth-related versus differentiation-specific promoters
LaRochelle et al. PDGF-D, a new protease-activated growth factor
Reubi et al. SST3-selective potent peptidic somatostatin receptor antagonists
Jacobsen et al. Differential targeting of nicotinic acetylcholine receptors by novel αA-conotoxins
SE9801148D0 (sv) New receptors
Tan et al. Characterization of Recombinant Extracellular Domain of Human Interleukin-10 Receptor (∗)
TR200200440T2 (tr) ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler
DE69230888D1 (de) Somatostatinrezeptoren
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
HUP0105337A2 (hu) Az immunválaszban szerepet játszó új polipeptidek
ATE106940T1 (de) Für das polypeptid des t-zellantigenreceptors kodierende nukleinsäure.
Bernat et al. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization
El Tayar et al. The lipophilicity of deuterium atoms. A comparison of shake-flask and HPLC methods
Tolan et al. Radioiodination of microgram quantities of ribosomal proteins from polyacrylamide gels
Malany et al. Orientation of α-neurotoxin at the subunit interfaces of the nicotinic acetylcholine receptor
Okamoto et al. Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2